Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Feb;89(2):221–227. doi: 10.1111/j.1349-7006.1998.tb00552.x

Role of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma

Akio Suzuki 1, Masakazu Toi 1,✉, Yutaka Yamamoto 1, Shigehira Saji 1, Mariko Muta 1, Takeshi Tominaga 1
PMCID: PMC5921757  PMID: 9548451

Abstract

Several oncoproteins or tumor suppressor gene products have been indicated to be of value as predictors of the de novo resistance to cytotoxic agents. In this study, we have investigated the role of MDM2 (murine double minutes) overexpression in doxorubicin resistance of breast cancer. Immunocytochemical analysis demonstrated that MDM2‐positive tumors, even with p53‐negative pheno‐type, were significantly more resistant to doxorubicin treatment compared to MDM2‐negative tumors. An in vitro experimental model using stable mdm2‐transfected MCF‐7 cells carrying wild‐type p53 confirmed that the cells become approximately 3‐fold more resistant to doxorubicin as a result of MDM2 overexpression, and the wild‐type p53 function, such as the induction of p21Waf1 following DNA damage, was significantly suppressed. MDM2 overexpression is suggested to be a novel marker for predicting lack of response to doxorubicin treatment in breast cancer patients.

Keywords: MDM2, Doxorubicin, p53, p21Waf1

Full Text

The Full Text of this article is available as a PDF (116.7 KB).

REFERENCES

  • 1. ) Cahilly‐Snyder , L. , Yang‐Feng , T. , Francke , U. and George , D. L.Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line . Somat. Cell Mol. Genet. , 13 , 235 – 244 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Fakharzadeh , S. S. , Trusko , S. P. and George , D. L.Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line . EMBO J. , 10 , 1565 – 1569 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. ) Oliner , J. D. , Kinzler , K. W. , Meltzer , P. S. , George , D. L. and Vogelstein , B.Amplification of a gene encoding a p53‐associated protein in human sarcomas . Nature , 358 , 80 – 83 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Momand , J. , Ambetti , G. P. , Olson , D. C. , George , D. and Levine , A. J.The mdm‐2 oncogene product forms a complex with the p53 protein and inhibits p53‐mediated transactivation . Cell , 69 , 1237 – 1245 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Barak , Y. , Juven , T. , Haffner , R. and Oren , M.mdm2 expression is induced by wild type p53 activity . EMBO J. , 12 , 461 – 468 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. ) Wu , X. , Bayle , J. H. , Olso , D. and Levine , A. J.The p53‐mdm2 autoregulatory feedback loop . Genes Dev. , 7 , 1126 – 1132 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Xiao , Z. X. , Chen , J. , Levine , A. J. , Modjtahedi , N. , Xing , J. , Sellers , W. R. and Livingston , D. M.Interaction between the retinoblastoma protein and the oncoprotein MDM2 . Nature , 375 , 694 – 698 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Martin , K. , Trouche , D. , Hagemeier , C. , Sørensen , T. S. , Thangue , N. B. and Kouzarides , T.Stimulation of E2F/DP1 transcriptional activity by MDM2 oncoprotein . Nature , 375 , 691 – 694 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Leach , F. S. , Tokino , T. , Meltzer , P. , Burrell , M. , Oliner , J. D. , Smith , S. , Hill , D. E. , Sidransky , D. , Kinzler , K. W. and Vogelstein , B.p53 mutation and MDM2 amplification in human soft tissue sarcomas . Cancer Res. , 53 , 2231 – 2234 ( 1993. ). [PubMed] [Google Scholar]
  • 10. ) Habuchi , T. , Kinoshita , H. , Yamada , H. , Kakehi , Y. , Ogawa , O. , Wu , W.‐J. , Takahashi , R. , Sugiyama , T. and Yoshida , O.Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification . J. Natl. Cancer Inst. , 86 , 1331 – 1335 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Reifenberger , G. , Liu , L. , Ichimura , K. , Schmidt , E. E. and Collins , V. P.Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations . Cancer Res. , 53 , 2736 – 2739 ( 1993. ). [PubMed] [Google Scholar]
  • 12. ) Waber , P. G. , Chen , J. and Nisen , P. D.Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas . Cancer Res. , 53 , 6028 – 6030 ( 1993. ). [PubMed] [Google Scholar]
  • 13. ) Quesnel , B. , Preudhomme , C. , Fourneier , J. , Fenaux , P. and Peyrat , J.‐P.MDM2 gene amplification in human breast cancer . Eur. J. Cancer , 30 , 982 – 984 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Inada , K. , Toi , M. , Yamamoto , Y. , Suzuki , A. , Kurisaki , T. , Suzuki , H. and Tominaga , T.Immunocytochemical analysis of MDM2 protein expression and its relevance to tumor angiogenesis in primary breast cancer . Oncol. Rep. , 3 , 667 – 671 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Lianes , P. , Orlow , I. , Zhang , Z. F. , Oliva , M. R. , Sarkis , A. S. , Reuter , V. E. and Cordon‐Cardo , C.Altered patterns of MDM2 and TP53 expression in human bladder cancer . J. Natl. Cancer Inst. , 86 , 1325 – 1330 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Marchetti , A. , Buttitta , F. , Gilando , S. , Palma , P. D. , Pellegrini , S. , Fina , P. , Douglioni , C. , Bevilacqua , G. and Barbareschi , M.mdm2 gene alterations and mdm2 protein expression in breast carcinoma . J. Pathol. , 175 , 31 – 38 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Baunoch , D. A. , Watkins , L. F. , Tewari , A. , Reece , M. T. , Adams , L. , Stack , R. , Brown , A. , Jones , L. , Christian , D. , Latif , N. A. , Lawrence , W. D. and Lane M. A.MDM2 overexpression in benign and malignant lesions of the human breast: association with ER expression . Int. J. Oncol. , 8 , 895 – 899 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Gudas , J. M. , Nguyen , H. , Klein , R. C. , Katayose , D. , Seth , P. and Cowan , K. H.Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells . Clin. Cancer Res. , 1 , 71 – 80 ( 1995. ). [PubMed] [Google Scholar]
  • 19. ) Sheikh , M. S. , Shao , Z. M. , Hussain , A. and Fontana , J. A.The p53‐binding protein MDM2 gene is differentially expressed in human breast carcinoma . Cancer Res. , 53 , 3226 – 3228 ( 1993. ). [PubMed] [Google Scholar]
  • 20. ) Sigalas , I. , Calvert , H. , Anderson , J. J. , Neal , D. E. and Lunec , J.Alteratively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer . Nat. Med. , 2 , 912 – 917 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Aas , T. , Borrensen , A. L. , Geisler , S. , Smith‐Sorensen , B. , Johnsen , H. , Varhaug , J. E. , Akslen , L. and Lonnin , P. E.Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients . Nat. Med. , 2 , 811 – 814 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Gusterson , B. A. , Gelber , R. D. , Goldhirsch , A. , Price , K. N. , Save‐Soderborgh , J. , Anbazhagan , R. , Styles , J. , Rudenstam , C. M. , Golouh , R. , Reed , R. , Martinetz‐Tello , F. , Tiltman , A. , Torhorst , J. , Grigolato , P. , Bettelheim , R. , Neville , A. M. , Burki , K. , Castiglione , M. , Collins , J. , Lindtner , J. and Senn , H. J.Prognostic importance of c‐erbB‐2 expression in breast cancer . J. Clin. Oncol. , 10 , 1049 – 1056 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Bartek , J. , Iggo , R. , Gannon , J. and Lane , D. P.Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines . Oncogene , 5 , 893 – 899 ( 1990. ). [PubMed] [Google Scholar]
  • 24. ) El‐Deiry , W. S. , Tokino , T. , Velculescu , V. E. , Levy , D. B. , Parsons , R. , Trent , J. M. , Lin , D. , Mercer , W. E. , Kinzler , K. W. and Vogelstein , B.Wafl, a potential mediator of p53 tumor suppression . Cell , 75 , 817 – 825 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Miyashita , T. , Krajewski , S. , Krajewska , M. , Wang , H. G. , Lin , H. K. , Liebermann , D. A. , Hoffman , B. and Reed , J. C.Tumor suppressor p53 is a regulator of bel‐2 and bax gene expression in vitro and in vivo . Oncogene , 9 , 1799 – 1805 ( 1994. ). [PubMed] [Google Scholar]
  • 26. ) Miyashita , T. , Harigai , M. , Hanada , M. and Reed , J. C.Identification of a p53 dependent negative response element in the bcl‐2 gene . Cancer Res. , 54 , 3131 – 3135 ( 1994. ). [PubMed] [Google Scholar]
  • 27. ) Fritsche , M. , Haesseler , C. and Brandner , G.Induction of nuclear accumulation of the tumor‐suppressor protein p53 by DNA‐damaging agents . Oncogene , 8 , 307 – 318 ( 1993. ). [PubMed] [Google Scholar]
  • 28. ) Roemer , K. and Friedmann , T.Modulation of cell proliferation and gene expression by a p53‐estrogen receptor hybrid protein . Proc. Natl. Acad. Sci. USA , 90 , 9252 – 9256 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. ) Carmicheal , J. , DeGraff , W. G. , Gazdar , A. F. , Minna , J. D. and Mitchell , J. B.Evaluation of tetrazolium‐based semi‐automated colorimetric assay: assessment of radiosensitivity . Cancer Res. , 47 , 943 – 946 ( 1987. ). [PubMed] [Google Scholar]
  • 30. ) Lowe , S. W. , Bodis , S. , McClatchey , A. , Remington , L. , Earl Ruley , H. , Fisher , D. E. , Housman , D. E. and Jacks , T.p53 status and the efficacy of cancer therapy in vivo . Science , 266 , 807 – 810 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Wang , X. W. , Yeh , H. , Schaeffer , L. , Roy , R. , Moncollin , V. , Egly , J. M. , Wang , Z. , Friedberg , E. C. , Evans , M. K. , Taffe , B. G. , Bohr , V. A. , Weeda , G. , Hoeijmakers , J. H. J. , Forrester , K. and Harris , C. C.p53 modulation of TFIIH‐associated nucleotide excision repair activity . Nat. Genet. , 10 , 188 – 195 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Bakalkin , G. , Yakovlena , T. , Selivanova , G. , Magnusson , K. P. , Szekeley , L. , Kisaleva , E. , Klein , G. , Terenius , L. and Wilman , K. G.p53 binds single‐stranded DNA ends and catalyzes DNA renaturation and strand transfer . Proc. Natl. Acad. Sci. USA , 91 , 413 – 417 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. ) Lee , S. , Elenbaas , B. , Levine , A. and Griffith , J.p53 and its 14kDa C‐terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches . Cell , 81 , 1013 – 1020 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Jayarman , L. and Privis , C.Activation of p53 sequence‐specific DNA binding by short single strand of DNA requires the p53 C‐terminus . Cell , 81 , 1021 – 1029 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Davis , P. , Bazar , K. , Huper , G. , Lozano , G. , Marks , J. and Iglehart , J. D.Dominance of wild‐type p53‐mediated transcriptional activation in breast epithelial cells . Oncogene , 13 , 1315 – 1322 ( 1996. ). [PubMed] [Google Scholar]
  • 36. ) Kondo , S. , Kondo , Y. , Hara , H. , Kaakaji , R. , Peterson , J. W. , Morimura , T. , Takeuchi , J. and Barnett , G. H.mdm2 gene mediates the expression of mdr gene and P‐glycoprotein in a human glioblastoma cell line . Br. J. Cancer , 74 , 1263 – 1268 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. ) Chen , J. , Marechal , V. and Levine , A. J.Mapping of the p53 and mdm‐2 interaction domains . Mol. Cell. Biol. , 13 , 4107 – 4144 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. ) Boddy , M. N. , Freemont , P. S. and Borden , K. L. B. , The p53‐associated protein MDM2 contains a newly characterized zinc‐finger domain called the RING finger . Trends Biochem. , 19 , 188 – 189 ( 1994. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES